Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

University of Washington School of Medicine, Seattle, WA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Seattle, WA
Treatments:ChemotherapyHospital:University of Washington School of Medicine
Drugs:Journal:Link
Date:Jun 2003

Description:

Patients: This phase I/II study involved a total of 49 women with recurrent platinum resistant ovarian or peritoneal cancer.

Treatment: The treatment consisted of two chemotherapy drugs - gemcitabine and doxorubicin.

Toxicity: Grade 4 toxicities included neutropenia and thrombocytopenia. Grade 3 toxicities inclded nausea, constipation, shortness of breath neurologic, metabolic, and fatigue.

Results: Median survival for the entire group was 12 months.

Support: The study was supported in part by Lilly Oncology. Eli Lilly manufactures or markets gemcitabine (Gemzar).

Correspondence: Barbara A. Goff, MD





Back